Effects of subtype-selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vascular restenosis

Circulation

Volumn 93, Issue 5, 1996, Pages 1009-1019

  Huckle, William R ^a   Drag, Marlene D ^a   Acker, Wayne R ^a   Powers, Michele ^a   McFall, Rosemary C ^a   Holder, Daniel J ^a   Fujita, Tsuneo ^a   Stabilito, Inez I ^a   Kim, Dooseop ^a   Ondeyka, Debra L ^a   Mantlo, Nathan B ^a   Chang, Raymond S L ^a   Reilly, Christopher F ^a   Schwartz, Robert S ^b   Greenlee, William J ^a   Johnson Jr , Robert G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MAYO CLINIC   (United States)

Author keywords

angioplasty; angiotensin; coronary disease; receptors; restenosis

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN; ANGIOTENSIN II ANTAGONIST; BENAZEPRILAT; CAPTOPRIL; CILAZAPRIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; L 163082; L 164282; LOSARTAN; N [3 [4 [2 (BUTOXYCARBONYLAMINOSULFONYL)PHENYL] 2 FLUOROBENZYL] 2 ETHYL 7 METHYLIMIDAZO[4,5 B]PYRIDIN 6 YL]BENZAMIDE; N [3 [4 [2 (TERT BUTOXYACETAMIDOSULFONYL)PHENYL] 2 FLUOROBENZYL] 2 METHYLIMIDAZO[4,5 B]PYRIDIN 6 YL]BENZAMIDE; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; RAMIPRIL; TRANDOLAPRIL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTENOSIS; SWINE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE;

EID: 9044223284     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.5.1009     Document Type: Article

References (77)

1. Ludbrook PA, ed. Coronary restenosis: its mechanisms and modification. Coron Artery Dis. 1993;4:225-259.
2. Herrman JPR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the Holy Grail? (part I). Drags. 1993;46:18-52.
3. Parandandi SN, Topol EJ. Contemporary clinical trials of restenosis. J Invasive Cardiol. 1994;6:109-124.
4. Katz AM. Angiotensin II: hemodynamic regulator or growth factor? J Mol Cell Cardiol. 1990;22:739-747.
5. Owens GK. Role of contractile agonists in growth regulation of vascular smooth muscle cells. Adv Exp Med Biol. 1991;308:71-79.
6. Huckle WR, Earp HS. Regulation of cell proliferation and growth by angiotensin II. Prog Growth Factor Res. 1994;5:177-194.
7. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245:186-188.
8. Powell JS, Muller RKM, Pouge M, Kuhn H, Hefti F, Baumgartner HR. The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol. 1990;16(suppl 4):S42-S49.
9. Capron L, Heudes D, Chajara A, Bruneval P. Effect of ramipril, an inhibitor of angiotensin converting enzyme, on the response of rat thoracic aorta to injury with a balloon catheter. J Cardiovasc Pharmacol. 1991;18:207-211.
10. 1 receptor antagonist: effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol. 1991;139:1291-1296.
11. Taguchi J, Abe J, Okazaki H, Ochiai M, Ohno M, Takuwa Y, Kurokawa K. Angiotensin converting enzyme inhibitors or DuP753 prevent neointimal formation following balloon injury with single topical or multiple systemic application. Biochem Biophys Res Commun. 1993;196:969-974.
12. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
13. Rakugi H, Jacob HJ, Krieger JE, Ingelfinger JR, Pratt RE. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation. 1993;87:283-290.
14. Shiota N, Okunishi H, Fukamizu A, Sakonjo H, Kikumori M, Nishimura T, Nakagawa T, Murakami K, Miyazaki M. Activation of two angiotensin-generating systems in the balloon-injured artery. FEBS Lett. 1993;323:239-242.
15. Rakugi H, Wang DS, Dzau VJ, Pratt RE. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation. 1994;90:449-455.
16. 1 receptors in neointima of rat aorta. J Clin Invest. 1992;90:1707-1712.
17. Clozel JP, Hess P, Michael C, Schietinger K, Baumgartner HR. Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs. Hypertension. 1991; 18(suppl II):II-55-II-59.
18. Lam JY, Lacoste L, Bourassa MG. Cilazapril and early atherosclerotic changes after balloon injury of porcine carotid arteries. Circulation. 1992;85:1542-1547.
19. Churchill DA, Siegel CO, Moinor ST, West MS, Raizner AE. Enalapril in the prevention of restenosis following intracoronary intervention in a swine model. Coron Artery Dis. 1993;4:461-467.
20. Huber KC, Schwartz RS, Edwards WD, Camrud AR, Bailey KR, Jorgenson MA, Holmes DJ. Effects of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary injury model. Am Heart J. 1993;125:695-701.
21. Hanson SR, Powell JS, Dodson T, Lumsden A, Kelly AB, Anderson JS, Clowes AW, Herker LA. Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension. 1991; 18(suppl II):II-70-II-76.
22. MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation. 1992;86:100-110.
23. Faxon DP, MARCATOR Study Group. Effects of high-dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol. 1995;2:362-369.
24. Desmet W, Vrolix M, DeScheerder I, Van Lierde J, Willems JL, Piessens J. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation. 1994;89:385-392.
25. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury: possible role in restenosis. J Clin Invest. 1994;93: 339-346.
26. Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, Kaneda Y, Ogihara T, Dzau VJ. Evidence for direct local effect of angiotensin in vascular hypertrophy: in vivo gene transfer of angiotensin converting enzyme. J Clin Invest. 1994;94:978-984.
27. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265: 22348-22357.
28. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol. 1993;62: 207-210.
29. Farhy RD, Carretero OA, Ho KL, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res. 1993;72:1202-1210.
30. 2) binding sites in R3T3 cells. Mol Pharmacol. 1991;40:360-367.
31. 2) binding sites in the rat pheochromocytoma PC12W cells. Eur J Pharmacol. 1992;227:63-70.
32. Pucell AG, Hodges JC, Sen I, Bumpus FM, Husain A. Biochemical properties of the ovarian granulosa cell type 2-angiotensin II receptor. Endocrinology. 1991;128:1947-1959.
33. Webb ML, Liu EC, Cohen RB, Hedberg A, Bogosian EA, Monshizadegan H, Molloy C, Serafino R, Moreland S, Murphy TJ, Dickinson KEJ. Molecular characterization of angiotensin II type II receptors in rat pheochromocytoma cells. Peptides. 1992;13: 499-508.
34. 2 receptor modulates T-type calcium current in non-differentiated NG108-15 cells. FEBS Lett. 1992;309:161-164.
35. Gyurko R, Kimura B, Kurian P, Crews FT, Phillips MI. Angiotensin II receptor subtypes play opposite roles in regulating phosphatidylinositol hydrolysis in rat skin slices. Biochem Biophys Res Commun. 1992;186:285-292.
36. 2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase. Biochem Biophys Res Commun. 1992;183: 206-211.
37. 2 receptors? Drug Dev Res. 1993;29:94-99.
38. Scheuer DA, Perrone MH. Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol. 1993;264:R917-R923.
39. Jaiswal N, Tallant EA, Jaiswal RK, Diz DI, Ferrario CM. Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine aortic smooth muscle cells: subtypes of angiotensin receptors involved. J Pharmacol Exp Ther. 1993;265:664-673.
40. Kang J, Sumners C, Posner P. Angiotensin II type 2 receptor-modulated changes in potassium currents in cultured neurons. Am J Physiol. 1993;265:C607-C616.
41. Hutchinson HG, Kim DK, Hein L, Kerwin WF, Pratt RE. Quantitative RT/PCR analysis of AT2 expression during vascular development and vascular injury. Circulation. 1994;90(suppl I):I-463. Abstract.
42. 1 receptor: gain of function study using gene transfer. Proc Natl Acad Sci U S A. 1995;92:10663-10667.
43. Osterrieder W, Muller RKM, Powell JS, Clozel JP, Hefti F, Baumgartner HR. Role of angiotensin II in injury-induced neointima formation in rats. Hypertension. 1991;18(suppl II):II-60-II-64.
44. Kauffman RF, Bean JS, Zimmerman KM, Brown RF, Steinberg MI. Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci. 1991;49:PL223-PL228.
45. Janiak P, Pillon A, Prost JF, Vilaine JP. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension. 1992;20:737-745.
46. Azuma H, Niimi Y, Hamasaki H. Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan. Br J Pharmacol. 1992;106:665-671.
47. Pratt RE, Wang D, Hein L, Dzau VJ. The AT2 isoform of the angiotensin receptor mediates myointimal hyperplasia following vascular injury. Hypertension. 1992;20:432. Abstract.
48. Kawamura M, Terashita ZI, Okuda H, Imura Y, Shino A, Nakao M, Nishikawa K. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats. J Pharmacol Exp Ther. 1993;266: 1664-1669.
49. Pan XM, Nelken N, Colyvas N, Rapp JH. Inhibition of injury induced intimal hyperplasia by saralasin in rats. J Vasc Surg. 1992; 15:693-698.
50. Laporte S, Escher E. Neointima formation after vascular injury is angiotensin 11 mediated. Biochem Biophys Res Commun. 1992;187: 1510-1516.
51. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation. 1990; 82:2190-2200.
52. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-274.
53. Chang RS, Siegl PK, Clineschmidt BV, Mantlo NB, Chakravarty PK, Greenlee WJ, Patchett AA, Lotti VJ. In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1992;262:133-138.
54. Mantlo NB, Chakravarty PK, Ondeyka DL, Siegl PKS, Chang RS, Lotti VJ, Faust KA, Chen TB, Schorn TW, Sweet CS, Emmert SE, Patchett AA, Greenlee WJ. Potent, orally active imidazo[4,5-(b)]pyridine-based angiotensin II receptor antagonists. J Med Chem. 1991;34:2919-2922.
55. 2 angiotensin II receptor antagonists. Bioorg Med Chem Lett. 1994;4:17-22.
56. 2 affinities. Bioorg Med Chem Lett. 1994;4:2011-2016.
57. Chard T. An Introduction to Radioimmunoassay and Related Techniques. Amsterdam, Netherlands: Elsevier; 1987.
58. Clowes A, Reidy M, Clowes M. Mechanisms of stenosis after arterial injury. Lab Invest. 1983;49:208-215.
59. Reilly CF, Fujita T, McFall RC, Stabilito II, Eng W, Johnson RG. Pharmacological and mechanistic aspects concerning the use of heparin and β-cyclodextrin tetradecasulfate for the treatment of vascular restenosis. Drug Dev Res. 1993;29:137-147.
60. Mosteller F, Tukey JW. DuJa Analysis and Regression. Reading, Mass: Addison-Wesley; 1977.
61. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res. 1985;56: 139-145.
62. Siegl PKS, Chang RSL, Mantlo NB, Chakravarty PK, Ondeyka DL, Greenlee WJ, Patchett AA, Sweet CS, Lotti VJ. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1992;262: 139-144.
63. Hodges JC, Hamby JM, Blankley CJ. Angiotensin II receptor binding inhibitors. Drugs Future. 1992;17:575-593.
64. Ferrell M, Fuster V, Gold HK, Chesebro JH. A dilemma for the 1990s: choosing appropriate experimental animal models for the prevention of restenosis. Circulation. 1992;85:1630-1631.
65. Muller DWM, Ellis SG, Topol EJ. Experimental models of coronary artery restenosis. J Am Coll Cardiol. 1992;19:418-432.
66. Steele PM, Chesebro JH, Stanson AW, Holmes DR, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty, natural history of the pathophysiological response to injury in a pig model. Circ Res. 1985;57:105-112.
67. Karas SP, Gravanis MB, Santoian EC, Robinson KA, Anderberg KA, King SB. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol. 1992;20:467-474.
68. Grinstead WC, Rodgers GP, Mazur W, French BA, Cromeens D, VanPelt C, West SM, Raizner AE. Comparison of three porcine restenosis models: the relative importance of hypercholesterolemia, endothelial abrasion, and stenting. Coron Artery Dis. 1994;5: 425-434.
69. Schwartz RS, Holmes DR, Veinot JP, Holder DJ, Camrud AR, Jorgenson MA, Johnson RG. Neointimal thickening after severe coronary artery injury is limited by short-term administration of a factor Xa inhibitor: results in a porcine model. Circulation. In press.
70. Srivatsa SS, Edwards WD, Simari RD, Holmes DR, Schwartz RS. Chronic hirudin infusion reduces neointimal thickening after injury in a porcine coronary model. J Am Coll Cardiol. 1995;February:302A. Abstract.
71. Jan Danser AH, Chowdury S, van der Giessen WJ, Schalekamp MADH, Saxena PR. Angiotensin II generation in isolated porcine coronary and carotid arteries. Br J Pharmacol. 1994;112:U219P. Abstract.
72. Campbell-Boswell M, Robertson AL. Effects of angiotensin II and vasopressin on human muscle cells in vitro. Exp Mol Pathol. 1981; 35:265-276.
73. Mii S, Ware JA, Mallette SA, Kent KC. Effect of angiotensin II on human vascular smooth muscle cell growth. J Surg Res. 1994;57: 174-178.
74. Bagby SP, Kirk EA, Mitchell LH, O'Reilly MM, Holden WE, Stenberg PE, Bakke AC. Proliferative synergy of Ang II and EGF in porcine aortic vascular smooth muscle cells. Am J Physiol. 1993; 265:F239-F249.
75. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth cell growth response to angiotensin II. J Clin Invest. 1993;91:2268-2274.
76. Casscells W. Migration of smooth muscle and endothelial cells. Circulation. 1992;86:723-729.
77. Bell L, Madri JA. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 1990;137:7-12.